Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting

References

• Goldhaber SZ. Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol. 1992;19(2):246–247.
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet.. 2012;379(9828):1835–1846.
   PubMed Web of Science ®Google Scholar
• Arshad N, Isaksen T, Hansen J-B, et al. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population. Eur J Epidemiol. 2017;32(4):299–305.
   PubMed Web of Science ®Google Scholar
• Lehnert P, Lange T, Møller CH, et al. Acute pulmonary embolism in a national Danish cohort: increasing incidence and decreasing mortality. Thromb Haemost. 2018;118(3):539–546.
   PubMed Web of Science ®Google Scholar
• White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23):I4–I8.
   PubMed Web of Science ®Google Scholar
• Albertsen IE, Nielsen PB, Søgaard M, et al. Risk of recurrent venous thromboembolism: a Danish nationwide cohort study. Am J Med. 2018;131(9):1067.e4–1074.e4.
   Web of Science ®Google Scholar
• Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3–10.
   PubMed Web of Science ®Google Scholar
• Mahan CE, Borrego ME, Woersching AL, et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012;108(2):291–302.
   PubMed Web of Science ®Google Scholar
• Willich SN, Chuang L-H, van Hout B, et al. Pulmonary embolism in Europe - burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res. 2018;170:181–191.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
   PubMed Web of Science ®Google Scholar
• Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis J. 2013;11(1):21.
   PubMedGoogle Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; Feb 18 129(7):764–772.
   PubMed Web of Science ®Google Scholar
• Hokusai V, Investigators Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; Oct 10 369(15):1406–1415.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford (UK):Oxford University Press; 2005.
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford (UK): Oxford University Press; 1996.
   Google Scholar
• Amgros. Guidelines for cost analyses of new medicines and indications in the hospital sector. Copenhagen: Amgros; 2018. (Report No.: 1.3).
   Google Scholar
• Hälsoekonomi – Tandvårds-Läkemedelförmånsverket [Internet]. Tandvårds-Läkemedelförmånsverket (TLV). 2019 [cited 2019 Jun 14]. Available from: https://www.tlv.se/lakemedel/halsoekonomi.html
   Google Scholar
• National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London (UK): NICE; 2014.
   Google Scholar
• Sundheds- og AEldreministeriet. Vejledning om udarbejdelse af sundhedsøkonomiske analyser af laegemidler. Copenhagen: Sundheds- og Ældreministeriet, Lægemiddelstyrelsen; 2018. (Report No.: VEJ nr 9153 af 09/03/2018).
   Google Scholar
• Garrison L, Towse AA. The drug budget silo mentality in Europe: an overview. Value Health. 2003;6(s1):S1.
   PubMedGoogle Scholar
• Poulsen PB, Johnsen SP, Hansen ML, et al. Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark. CEOR. 2017;9:617–627.
   Google Scholar
• Danish Medicines Agency. PRODUKTRESUMÉ for Warfarin Orion [Internet]. Copenhagen (Denmark): DMA; 2019 [cited 2019 May 14]. Available from: www.produktresume.dk
   Google Scholar
• Danish Medicines Agency. PRODUKTRESUMÉ for Klexane [Internet]. Copenhagen (Denmark): DMA; 2009. [cited 2019 May 14]. Available from: www.produktresume.dk
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics – Apixaban. Amsterdam: EMA; 2018 [cited 2019 May 14]. Available from https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_da.pdf.
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics – Rivaroxaban. Amsterdam: EMA; 2018 [cited 2019 May 14]. Available from https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_da.pdf
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics – Dabigatran. Amsterdam: EMA; 2018 [cited 2019 May 14]. https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_da.pdf
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics – Edoxaban. Amsterdam: EMA; 2018 [cited 2019 May 14]. Available from https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_da.pdf
   Google Scholar
• Nielsen JD, Grove EL, Larsen TB, et al. Recidiv af venøs tromboemboli [Recurrence of venous thromboembolism]. Ugeskr Laeger 2018; 180(20A):V03180177.
   Google Scholar
• Organisation of General Practitioners in Denmark (PLO). Takstkatalog [Charge catalogue for the general practice in Denmark]. Copenhagen: PLO; 2019.
   Google Scholar
• Sundhedsdatastyrelsen. Takstsystem, vejledning 2017 [Tariff system, guideline]. DRG og Finansiering, Sundhedsdatastyrelsen. Version 26-1. Copenhagen, December 2016.
   Google Scholar
• Gustafsson N, Stallknecht SE, Skovdal M, et al. Societal costs due to meningococcal disease: a national registry-based study. Clinicoecon Outcomes Res. 2018;10:563–572.
   PubMed Web of Science ®Google Scholar
• de Jong LA, Dvortsin E, Janssen KJ, et al. Cost-effectiveness analysis for apixaban in the acute treatment and prevention of venous thromboembolism in the Netherlands. Clin Ther. 2017;39(2):288.e4–302.e4.
   Web of Science ®Google Scholar
• Bamber L, Muston D, McLeod E, et al. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J. 2015; [cited 2019 Jun 2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464718/
   PubMed Web of Science ®Google Scholar